$8.54
1.04% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US3596161097
Symbol
FULC
Sector
Industry

Fulcrum Therapeutics Inc Stock price

$8.54
-0.33 3.72% 1M
-3.46 28.83% 6M
+1.79 26.52% YTD
+2.93 52.23% 1Y
-19.53 69.58% 3Y
-3.43 28.66% 5Y
-4.96 36.74% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.09 1.04%
ISIN
US3596161097
Symbol
FULC
Sector
Industry

Key metrics

Market capitalization $532.90m
Enterprise Value $268.77m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.29
P/S ratio (TTM) P/S ratio 6.53
P/B ratio (TTM) P/B ratio 1.94
Revenue growth (TTM) Revenue growth 2,582.55%
Revenue (TTM) Revenue $81.63m
EBIT (operating result TTM) EBIT $-32.77m
Free Cash Flow (TTM) Free Cash Flow $-12.62m
Cash position $273.78m
EPS (TTM) EPS $-0.35
P/E forward negative
P/S forward 6.63
EV/Sales forward 3.34
Short interest 16.27%
Show more

Is Fulcrum Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Fulcrum Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Fulcrum Therapeutics Inc forecast:

7x Buy
88%
1x Sell
13%

Analyst Opinions

8 Analysts have issued a Fulcrum Therapeutics Inc forecast:

Buy
88%
Sell
13%

Financial data from Fulcrum Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
82 82
2,585% 2,585%
100%
- Direct Costs 1.89 1.89
20% 20%
2%
80 80
11,457% 11,457%
98%
- Selling and Administrative Expenses 38 38
4% 4%
46%
- Research and Development Expense 73 73
10% 10%
89%
-31 -31
71% 71%
-38%
- Depreciation and Amortization 1.89 1.89
20% 20%
2%
EBIT (Operating Income) EBIT -33 -33
69% 69%
-40%
Net Profit -20 -20
79% 79%
-25%

In millions USD.

Don't miss a Thing! We will send you all news about Fulcrum Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fulcrum Therapeutics Inc Stock News

Neutral
GlobeNewsWire
11 days ago
CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a series of investor meetings at the following conferences:
Neutral
GlobeNewsWire
15 days ago
CAMBRIDGE, Mass., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum granted stock options to purchase shares of the ...
Neutral
GlobeNewsWire
20 days ago
CAMBRIDGE, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of Isabel Kalofonos as chief commercial officer and Heather Faulds as chief regulatory affairs & quality ...
More Fulcrum Therapeutics Inc News

Company Profile

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Alexander Sapir
Employees 76
Founded 2015
Website www.fulcrumtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today